Company: CSL Behring
Job title: Executive Director & Global Therapeutic Area Head, Hematology, Clinical Research & Development
Brahm Goldstein, MD, MCR joined CSL Behring in 2018 and is the Therapeutic Area Head for Hematology & Thrombosis and Executive Director, Clinical Research and Development in King of Prussia, PA, USA. Brahm has an MD degree from SUNY Health Science Center and a Masters in Clinical Research from Oregon Health & Science University. He has held leadership roles in the biotechnology and pharmaceutical industry for the past 13 years at several companies including Novo Nordisk, Ikaria/Bellerophan, Baxter, Shire, and Global Blood Therapeutics. Prior to transitioning to the pharmaceutical industry, Brahm was in academic medicine for over 25 years as a pediatric critical care physician with positions at Massachusetts General Hospital/Harvard Medical School, University of Rochester School of Medicine and Dentistry, and Oregon Health & Sciences University. He currently leads the CSL high-performing clinical development team in hematology over multiple disease areas including hemophilia A and B, von Willebrand disease, sickle cell disease, and acquired bleeding disorders.
Live Presenter Q&A 2:25 pm
day: Day One
An Approach Towards Safe and Effective Extended 14 and 21-Day Dosing with rFIX-FP in Hemophilia B 2:05 pm
• Extended dosing with rFIX-FP should be based upon an individual’s pharmacokinetic and clinical response- Allowing an adequate observation period during an extended dosing trial is key to establish safety and effectiveness • Following a clear and strategic dosing strategy, safe and effective extended dosing in hemophilia B patients is possibleRead more
day: Day One